Cancer patients should not take chemotherapy, radiotherapy or biological therapy (or should stop them) and follow the Tayebat system instead; 'we are against the word medicine'.
Original statement
خطر العلاج بيولوجي وو علاج كيماوي يا باشا احنا ضد كلمه دوا اصلا على وجه الارض
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Cancer patients should not take chemotherapy, radiotherapy or biological therapy (or should stop them) and follow the Tayebat system instead; 'we are against the word medicine'.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- السرطان ١ (Open source)
- Published
- 26 January 2025
- Timestamp
- 1:03:31 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Claimed mechanism
Cancer is the body's own plan; chemo harms own cells
- Claimed health effect
Avoid oncologic therapy
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Diverging source versions
ما فيش حاجه اسمها علاج كيماوي ياط كل افتراضات في السرطان غلط
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- هدفنا حياة بلا مرض مزعوم (Open source)
- Published
- 29 January 2025
- Timestamp
- 0:28:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
ناهد رشيدي من حالات سرطان الثدي اللي اتعفت معانا بفضل الله نائد رشيدي مشيت على نظامنا وبس وما اخدناش كيماوي وما اخدناش اشعاع وما استاصلناش ثدي ولا استاصلنا الورم
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (Open source)
- Published
- 26 March 2026
- Timestamp
- 0:24:59 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
امي ماشيه على النظام وعندها سرطان ثدي عامت عمليه ومش حابه تعمل كيماوي طبعا ما تعملش كيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- زرع الكلي ： الحمد لله مناقشة حرة (Open source)
- Published
- 16 February 2025
- Timestamp
- 0:35:19 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
واحنا وقفنا يا جماعه الكيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live! مصير الهيموجلوبين (Open source)
- Published
- 13 May 2025
- Timestamp
- 0:24:04 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
واللي خد كيماوي ياخد يا باشا واللي ياخد اشعاع ياخد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! النخاميه (Open source)
- Published
- 25 June 2025
- Timestamp
- 0:45:48 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
قالت ادوها كيماوي قامت واقفه مع الدكتوره خذت الكيماوي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- سرطان الرئةالحمد لله في ٥ شهور❤️❤️❤️❤️ (Open source)
- Published
- 26 February 2024
- Timestamp
- not available (transcript has no timings)
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Rejection of chemotherapy, radiotherapy and biologicals; presentation of patients who refused or stopped chemotherapy as successes.
2. What is demonstrably correct?
Elawady sometimes said patients decide themselves (P86iybRnOE4: those who want chemo may take it). End-of-life chemotherapy is often not beneficial (C-CHM-07). Side effects are real (C-CHM-01..06).
3. What is wrong or exaggerated?
In curable cancers, refusing chemotherapy, radiotherapy or surgery costs lives: alternative-only treatment HR 2.50 for death (breast cancer HR 5.68) (I-CHM-03); excess mortality with complementary medicine was mediated by refusal of conventional therapy (I-CHM-04); chemotherapy reduces breast-cancer mortality by about one-third (I-CHM-01); childhood ALL survival 90% (I-CHM-05). Even delays matter: in observational data, each 4-week delay (studied range about 4-16 weeks, in patients who were eventually treated) was associated with higher mortality (I-CHM-07); this concerns delay, not refusal. Individual reports of patients doing well without chemotherapy (e.g., after surgery) cannot show that the diet caused the outcome.
4. What remains unclear?
The outcomes of the specific patients mentioned in the videos are not verifiable.
5. Which studies support it?
None for the claim.
6. Which studies contradict it?
I-CHM-01, I-CHM-02, I-CHM-03, I-CHM-04, I-CHM-05, I-CHM-07.
7. What applies to Germany and Europe?
Standard of care in Europe.
8. What is known about Egypt?
Standard of care in Egypt follows the same evidence.
9. What practical conclusion is appropriate?
Never replace indicated cancer treatment with a diet; nutrition questions should be discussed with the oncology team.
Assessment details
- Rationale for certainty of evidence
Randomised trials and large registries consistently show survival benefit of indicated treatment and excess mortality with refusal or delay.
- Source quality
Multiple machine transcripts; consistent pattern with some contrary statements.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
In several videos Dr. Diaa spoke against chemotherapy, radiotherapy and biological drugs, and presented patients who stopped chemotherapy as successes. The scientific evidence is clear: for many cancers these treatments greatly increase the chance of survival. People who replace them with alternative methods die much more often, for breast cancer about five times as often in one large study. Individual stories cannot show that a diet cured a cancer.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (6)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta-analysisindependent cross-checkfull text checked★ key studyIn 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Refusing chemo forgoes ~1/3 mortality reduction
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta-analysisindependent cross-checkfull text checked★ key studyRecurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Refusing RT increases recurrence
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure radiotherapy benefit.
- How was the study done?
IPD meta-analysis.
- How many people, animals or samples were studied?
10,801 women.
- What was actually found?
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- How large was the observed effect?
-15.7% recurrence; -3.8% death.
- What do the results mean in everyday life?
Radiotherapy markedly lowers the chance the cancer returns.
- What are the study's limitations?
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit size without risk factors.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract only checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
AM only: HR 2.50
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487Cohort studyindependent cross-checkabstract only checked★ key studyUsers of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
Refusal mediates excess mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Study CM and survival.
- How was the study done?
Registry cohort.
- How many people, animals or samples were studied?
258 vs 1,032.
- What was actually found?
HR 2.08; explained by refusal.
- How large was the observed effect?
5-y OS 82.2% vs 86.6%.
- What do the results mean in everyday life?
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusal advice.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Causal effect of any single CM.
-
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018Cohort studyindependent cross-checkabstract only checked★ key study5-year survival in childhood ALL rose to 90.4% by 2000-2005.
Cure with chemo
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track ALL survival.
- How was the study done?
Trial cohort analysis.
- How many people, animals or samples were studied?
21,626.
- What was actually found?
83.7% -> 90.4%.
- How large was the observed effect?
+6.7 points.
- What do the results mean in everyday life?
Childhood leukaemia is usually curable with treatment.
- What are the study's limitations?
Trial patients.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Survival outside trials.
-
Each month of delay in cancer treatment raises the risk of death
Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087Meta-analysisindependent cross-checkfull text checked★ key studyFor example, every 4-week delay of breast surgery was linked to 8% higher mortality.
Delay raises mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Quantify harm from delay.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
1.27 million patients.
- What was actually found?
Higher mortality with delay.
- How large was the observed effect?
HR 1.06-1.08 per 4 weeks (surgery).
- What do the results mean in everyday life?
Do not postpone recommended treatment.
- What are the study's limitations?
Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.
- What does it say about Elawady's specific claim?
Safety.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Standard of care in Europe.
Egypt
Standard of care in Egypt follows the same evidence.
What applies in my country?
General scientific assessment
False Advice to avoid or stop chemotherapy and radiotherapy for a diet contradicts strong evidence and can be life-threatening.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
- Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087